Yenizin is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Yenizin is used to treat cold or allergy symptoms such as sneezing, itching, watery eyes, or runny nose.
Yenizin is also used to treat itching and swelling caused by chronic urticaria (hives).
Yenizin may also be used for purposes not listed in this medication guide.
Yenizin indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Perennial Allergic Rhinitis: Yenizin syrup is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing.
Chronic Urticaria: Yenizin syrup is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 5 years of age. It significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus.
How should I use Yenizin?
Use Yenizin orally disintegrating tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Do not remove the blister unit from the carton until you are ready to take Yenizin orally disintegrating tablets. Make sure that your hands are dry when you open the blister unit. Do not push the tablet through the foil. Peel back the foil on the blister unit and place the tablet on your tongue. The tablet dissolves quickly and can be swallowed with saliva. Yenizin orally disintegrating tablets may be taken with or without water. Take the tablet immediately after opening the blister unit. Do not store the removed tablet for future use.
If you miss a dose of Yenizin orally disintegrating tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Yenizin orally disintegrating tablets.
Uses of Yenizin in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
Use: Labeled Indications
Oral:
Allergic rhinitis: Relief of symptoms associated with allergic rhinitis.
Urticaria, chronic spontaneous: Treatment of uncomplicated skin manifestations of chronic spontaneous urticaria.
Injection:
Urticaria, acute: Treatment of acute urticaria.
Off Label Uses
Anaphylaxis (adjunct to epinephrine for relief of cutaneous symptoms)
Based on joint guidelines from the American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma & Immunology, and Joint Council of Allergy, Asthma and Immunology on the diagnosis and management of anaphylaxis and guidelines from the World Allergy Organization on anaphylaxis, Yenizin may be used as adjunctive treatment, although should not be used as monotherapy or as first-line therapy of anaphylaxis.
Angioedema, acute allergic or recurrent idiopathic
Clinical experience suggests the utility of second-generation H receptor antagonists (eg, Yenizin) for the treatment of acute allergic or recurrent idiopathic angioedema.
Yenizin description
sponsored
Yenizin HCl is a piperazine derivative and a metabolite of hydroxyzine. It competes reversibly with histamine to block the histamine (H1) receptor sites. Yenizin HCl is considered a long-acting nonsedating antihistamine and has some mast-cell stabilizing activity.
Yenizin dosage
Yenizin Dosage
Applies to the following strength(s): 10 mg; 5 mg; 1 mg/mL
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
Allergic Rhinitis
Urticaria
Usual Pediatric Dose for:
Allergic Rhinitis
Urticaria
Additional dosage information:
Renal Dose Adjustments
Liver Dose Adjustments
Precautions
Dialysis
Usual Adult Dose for Allergic Rhinitis
5 to 10 mg orally or chewed once a day
Usual Adult Dose for Urticaria
5 to 10 mg orally or chewed once a day
Usual Pediatric Dose for Allergic Rhinitis
6 months to 2 years: 2.5 mg orally once a day, 12 months and older may be increased to 2.5 mg orally twice a day.
2 to 5 years: 2.5 mg orally once a day, may be increased to 5 mg/day in 1 to 2 divided doses.
6 years or older: 5 to 10 mg orally or chewed once a day.
Usual Pediatric Dose for Urticaria
6 months to 2 years: 2.5 mg orally once a day, 12 months and older may be increased to 2.5 mg orally twice a day.
2 to 5 years: 2.5 mg orally once a day, may be increased to 5 mg/day in 1 to 2 divided doses.
6 years or older: 5 to 10 mg orally or chewed once a day.
Renal Dose Adjustments
CrCl less than 30 mL/min: 5 mg orally or chewed once a day.
Use of Yenizin is not recommended in children under 6 years of age with renal impairment due to the difficulty in reliably administering doses less than 2.5 mg (1/2 teaspoonful) and the lack of pharmacokinetic and safety information of Yenizin in such patients.
Liver Dose Adjustments
5 mg orally or chewed once a day
Use of Yenizin is not recommended in children under 6 years of age with hepatic impairment due to the difficulty in reliably administering doses less than 2.5 mg (1/2 teaspoonful) and the lack of pharmacokinetic and safety information of Yenizin in such patients.
Precautions
In clinical trials, the occurrence of somnolence has been reported. Due caution should therefore be exercised when driving a car or operating potential dangerous machinery. Concurrent use of alcohol or other CNS depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.
Dialysis
Yenizin is not significantly removed by hemodialysis, thus supplementary dosing is not required following hemodialysis. The recommended dosage for patients on hemodialysis is 5 mg orally or chewed once a day.
More about Yenizin
Side Effects
During Pregnancy or Breastfeeding
Dosage Information
Drug Images
Drug Interactions
Support Group
Pricing & Coupons
139 Reviews - Add your own review/rating
Consumer resources
Yenizin
Yenizin chewable tablets
Yenizin orally disintegrating tablets
Yenizin solution
Other brands: Zyrtec, Children's Zyrtec, Zyrtec Hives, Yenizin, More (1) »
Tablet: Concurrent use with alcohol may potentiate the CNS depressant effects of Yenizin; maprotiline or tricyclic antidepressants may potentiate the anticholinergic effects of either these medications or Yenizin.
Monoamine oxidase (MAO) inhibitors are not recommended because the use may prolong and intensify the anticholinergic and CNS depressant effects of Yenizin.
Concurrent use with ototoxic medications may mask the symptoms of ototoxicity eg, tinnitus, dizziness or vertigo; photosensitizing medications may cause additive photosensitizing effects.
Syrup: No interaction is observed for Yenizin with pseudoephedrine, cimetidine, ketoconazole, erythromycin and azithromycin. Small decrease in Yenizin clearance is observed when theophylline (400 mg once daily) is taken with Yenizin. However, disposition of theophylline was not altered by concomitant Yenizin administration. Concomitant administration of Yenizin and macrolides or ketoconazole has never resulted clinically relevant EGG changes. Extent of exposure to Yenizin was increased by 40% when ritonavir is taken with Yenizin. Disposition of ritonavir was slightly altered further to concomitant Yenizin administration.
Pediatric studies were conducted with Yenizin. More than 1300 pediatric patients aged 6 to 11 years with more than 900 treated with Yenizin at doses of 1.25 to 10 mg per day were included in controlled and uncontrolled clinical trials conducted in the United States. The duration of treatment ranged from 2 to 12 weeks. Placebo-controlled trials up to 4 weeks duration included 168 pediatric patients aged 2 to 5 years who received Yenizin, the majority of whom received single daily doses of 5 mg. A placebo-controlled trial 18 months in duration included 399 patients aged 12 to 24 months treated with Yenizin (0.25 mg/kg bid), and another placebo-controlled trial of 7 days duration included 42 patients aged 6 to 11 months who were treated with Yenizin (0.25 mg/kg bid).
The majority of adverse reactions reported in pediatric patients aged 2 to 11 years with Yenizin were mild or moderate. In placebo-controlled trials, the incidence of discontinuations due to adverse reactions in pediatric patients receiving up to 10 mg of Yenizin was uncommon (0.4% on Yenizin vs. 1.0% on placebo).
Table 1 lists adverse experiences which were reported for Yenizin 5 and 10 mg in pediatric patients aged 6 to 11 years in placebo-controlled clinical trials in the United States and were more common with Yenizin than placebo. Of these, abdominal pain was considered treatment-related and somnolence appeared to be dose-related, 1.3% in placebo, 1.9% at 5 mg and 4.2% at 10 mg. The adverse experiences reported in pediatric patients aged 2 to 5 years in placebo-controlled trials were qualitatively similar in nature and generally similar in frequency to those reported in trials with children aged 6 to 11 years.
In the placebo-controlled trials of pediatric patients 6 to 24 months of age, the incidences of adverse experiences, were similar in the Yenizin and placebo treatment groups in each study. Somnolence occurred with essentially the same frequency in patients who received Yenizin and patients who received placebo. In a study of 1 week duration in children 6 to 11 months of age, patients who received Yenizin exhibited greater irritability/fussiness than patients on placebo. In a study of 18 months duration in patients 12 months and older, insomnia occurred more frequently in patients who received Yenizin compared to patients who received placebo (9.0% v. 5.3%). In those patients who received 5 mg or more per day of Yenizin as compared to patients who received placebo, fatigue (3.6% v. 1.3%) and malaise (3.6% v. 1.8%) occurred more frequently.
Table 1.
Adverse Experiences Reported in Pediatric Patients Aged 6 to 11 Years in Placebo-Controlled United States Yenizin Trials (5 or 10 mg Dose) Which Occurred at a Frequency of ≥2% in Either the 5-mg or the 10-mg Yenizin Group, and More Frequently Than in the Placebo Group
Adverse Experiences
Placebo
(N=309)
Yenizin
5 mg
(N=161)
10 mg
(N=215)
Headache
12.3%
11.0%
14.0%
Pharyngitis
2.9%
6.2%
2.8%
Abdominal pain
1.9%
4.4%
5.6%
Coughing
3.9%
4.4%
2.8%
Somnolence
1.3%
1.9%
4.2%
Diarrhea
1.3%
3.1%
1.9%
Epistaxis
2.9%
3.7%
1.9%
Bronchospasm
1.9%
3.1%
1.9%
Nausea
1.9%
1.9%
2.8%
Vomiting
1.0%
2.5%
2.3%
The following events were observed infrequently (less than 2%), in either 3982 adults and children 12 years and older or in 659 pediatric patients aged 6 to 11 years who received Yenizin in U.S. trials, including an open adult study of six months duration. A causal relationship of these infrequent events with Yenizin administration has not been established.
Special Senses: parosmia, taste loss, taste perversion.
Vision: blindness, conjunctivitis, eye pain, glaucoma, loss of accommodation, ocular hemorrhage, xerophthalmia.
Body as a Whole: accidental injury, asthenia, back pain, chest pain, enlarged abdomen, face edema, fever, generalized edema, hot flashes, increased weight, leg edema, malaise, nasal polyp, pain, pallor, periorbital edema, peripheral edema, rigors.
Occasional instances of transient, reversible hepatic transaminase elevations have occurred during Yenizin therapy. Hepatitis with significant transaminase elevation and elevated bilirubin in association with the use of Yenizin has been reported.
Post-Marketing Experience
In the post-marketing experience period, the following additional rare, but potentially severe adverse events have been reported: aggressive reaction, anaphylaxis, cholestasis, convulsions, glomerulonephritis, hallucinations, hemolytic anemia, hepatitis, orofacial dyskinesia, severe hypotension, stillbirth, suicidal ideation, suicide and thrombocytopenia.
Tablet: Yenizin should not be used except under special circumstances for patients with hepatic and renal function impairment.
The risk-benefit should be considered when medical problems eg, bladder neck obstruction, prostatic hypertrophy, urinary retention and glaucoma exists.
Syrup: Hypersensitivity to Yenizin dihydrochloride, hydroxyzine, any piperazine derivatives or to any of the excipients of Yenizin. Patients with severe renal impairment CrCl <10 mL/min. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Yenizin.
DailyMed. "CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Yenizin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Yenizin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
3 consumers reported age
Users
%
1-5
2
66.7%
6-15
1
33.3%
Consumer reviews
There are no reviews yet. Be the first to write one!
